S-1/A: Allarity Therapeutics Seeks $10 Million in Public Offering Amid Nasdaq Delisting Concerns

Allarity Therapeutics is offering 5,000,000 shares of common stock at an assumed price of $2.00 per share to raise capital while facing potential delisting from the Nasdaq Capital Market.

Summary

• Allarity Therapeutics is conducting a public offering of 5,000,000 shares of its common stock.
• The assumed offering price is $2.00 per share, based on the last reported sale price on Nasdaq on April 15, 2024.
• The company intends to use the net proceeds of approximately $8.9 million (or $10.3 million if the underwriters' option is fully exercised) for license agreement payments, stenoparib clinical trials, outstanding payables, and general corporate purposes.
• 3i, LP, a major stockholder, may participate in the offering, and Allarity intends to use those proceeds to repurchase Series A Preferred Stock.
• Allarity is facing potential delisting from Nasdaq due to non-compliance with listing rules.
• The company received an extension until April 24, 2024, to regain compliance.
• The offering is subject to a 45-day over-allotment option for the underwriters to purchase up to 714,286 additional shares.
• The company has granted the representative or its designees warrants to purchase up to a total of shares of our common stock ( % of the aggregate number of shares of common stock sold in this offering).
• The company is an emerging growth company and a smaller reporting company, allowing for reduced disclosure requirements.

Sentiment

Score: 4

Explanation: The document presents a mixed sentiment. While the company is actively pursuing a capital raise to fund its operations, it is also facing significant challenges, including potential delisting from Nasdaq and the termination of a key license agreement. The high degree of risk associated with investing in the company's securities further contributes to the negative sentiment.

Positives

• The offering will provide Allarity with additional capital to fund its operations, particularly the stenoparib clinical trials.
• The potential participation of 3i, LP, could strengthen the company's financial position.
• The company has an extension to regain compliance with Nasdaq listing rules.
• The company has granted the representative or its designees warrants to purchase up to a total of shares of our common stock ( % of the aggregate number of shares of common stock sold in this offering).

Negatives

• The company is facing potential delisting from Nasdaq, which could negatively impact its stock price and ability to raise capital.
• The offering will dilute existing stockholders' ownership.
• The company has a history of non-compliance with Nasdaq listing standards.
• The company has a history of losses and is dependent on raising additional capital.
• The company received a termination notice from Novartis Pharma AG due to a material breach of a license agreement.

Risks

• Failure to satisfy Nasdaq continued listing requirements could lead to delisting.
• The use of proceeds from 3i may not increase the value of your investment.
• New investors will experience immediate and substantial dilution.
• The company's business developments may not meet investor expectations.
• The price of shares of common stock has fluctuated substantially.
• The company is subject to penalties if it fails to meet certain conditions of the Certificate of Designations of the Series A Preferred Stock.
• The company's continued operations are dependent on raising capital.
• Future sales, or the perception of future sales, by the company or its stockholders could cause the market price for shares of common stock to decline.
• There is no assurance that an active and liquid trading market in shares of common stock will develop.
• The company's Certificate of Incorporation and bylaws, and Delaware law, may have anti-takeover effects that could discourage, delay or prevent a change in control, which may cause the stock price to decline.
• The company received a request for documents from the SEC in the investigation known as In the Matter of Allarity Therapeutics, Inc., and, separately, a letter from Nasdaq, regarding the same matter, the consequences of which are unknown.

Future Outlook

The company intends to use the net proceeds of this offering towards potential payments under license agreements, continuation of our stenoparib clinical trials, payment of outstanding account payables and accrued liabilities, and working capital and general corporate purposes.

Management Comments

• Mr. Jensen is currently in the process of streamlining the organization and its finances to fuel the focused development of stenoparib in ovarian cancer.

Industry Context

The announcement reflects the challenges faced by clinical-stage pharmaceutical companies in securing funding and navigating regulatory hurdles, particularly in the competitive oncology space.

Comparison to Industry Standards

• The company's reliance on the DRP platform for patient selection is similar to precision medicine approaches used by companies like Foundation Medicine (acquired by Roche) and Guardant Health.
• The company's focus on in-licensing clinical-stage assets is a common strategy in the biotech industry, comparable to companies like Arcus Biosciences and Relay Therapeutics.
• The company's financial situation and Nasdaq delisting concerns are similar to those faced by other small-cap biotech companies struggling to fund their drug development programs.

Management Changes

Legal Proceedings

• The company received a request for documents from the SEC in the investigation known as In the Matter of Allarity Therapeutics, Inc., and, separately, a letter from Nasdaq, regarding the same matter, the consequences of which are unknown.

Related Party Transactions

• The document details numerous transactions with 3i, LP, including loans, securities purchases, and amendments to agreements.

Stakeholder Impact

• Shareholders will experience dilution due to the public offering.
• Employees face uncertainty due to the company's financial situation and potential delisting.
• The company's ability to continue developing its drug candidates impacts patients with difficult-to-treat cancers.
• Creditors and suppliers face increased risk due to the company's financial challenges.

Next Steps

• The company needs to successfully complete the public offering.
• Allarity must regain compliance with Nasdaq listing rules by April 24, 2024.
• The company needs to continue the clinical development of stenoparib.
• The company intends to formally memorialize its new arrangement with Mr. Jensen by amending the Consultancy Agreement (the Amendment) to (i) clarify the scope of services to be provided by Mr. Jensen, (ii) increase the compensation to be paid to Mr. Jensen and (iii) extend the term of the Consultancy Agreement to December 1, 2024.

Key Dates

Keywords

Allarity Therapeutics, public offering, common stock, Nasdaq, delisting, stenoparib, 3i LP, capital raise, clinical trials, DRP platform